Movement Alert|Iovance Biotherapeutics, Inc. Falls 5.25% in Regular Trading, Market Reassesses Unchanged Full-Year Revenue Guidance After Q3 Beat

Market Focus11-12

On November 12, Iovance Biotherapeutics, Inc. fell 5.25% in Regular Trading, trading at $7.68 per share, with turnover of $15.37 million.

The move followed a market reassessment after the company’s recent third-quarter results beat expectations on both earnings and revenue, but full-year product revenue guidance remained unchanged at $410 million to $420 million rather than being raised again.

For the quarter ended September 30, Iovance Biotherapeutics, Inc. reported a loss of $0.05 per share, better than consensus expectations of a $0.08 to $0.09 loss, while revenue rose to $121.5 million from $67.5 million a year earlier and topped expectations of about $116 million. Despite continued commercialization progress and narrower losses, the maintained guidance appears to have limited incremental upside after the sharp guidance increase disclosed in late September.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment